Hong Kong Buybacks Hit a Record. But Companies Spent Less.

Hong Kong-listed companies repurchased far more of their own shares this year — yet spent less money doing it than they did last year. The gap comes down to price, not appetite: shares got cheaper, so the same cash bought more stock, and the picture is far more concentrated than the headline suggests.

More Shares, Less Money: The Math Behind the Headline

On Sept. 4, the Shanghai Securities News, citing market statistics, reported that as of Sept. 3, buybacks by Hong Kong-listed companies this year had topped HK$100 billion, reaching HK$109.413 billion (about US$14 billion) across 8.24 billion shares. The number of shares repurchased jumped 55.4% from a year earlier. Over the same window, the Hang Seng Index dipped 1.63% year to date.

Buried in the same report was a second figure that's easy to miss: the HK$109.413 billion total was lower than the comparable figure last year. Working the math backward, buybacks in the year-earlier period came to roughly 5.3 billion shares for more money than this year's 8.24 billion shares bought — meaning companies have generally been transacting at lower share prices than a year ago. That divergence suggests companies are buying more aggressively into a lower-valuation window, not that they suddenly have more cash to return to shareholders.

Five Companies Account for More Than Half the Total

The buying is also concentrated. According to the Shanghai Securities News tally, the top five buyers by value as of Sept. 3 were Tencent Holdings (HK$29.432 billion), AIA Group (HK$13.635 billion), Xiaomi Group-W (HK$11.814 billion), China Hongqiao (HK$5.287 billion) and ZTO Express-W (HK$3.269 billion). Together, the five accounted for HK$63.437 billion — roughly 58% of all buyback value, with Tencent alone making up nearly 27%. The list spans information technology, financials, consumer discretionary, logistics and cyclical sectors.

"HK$100 billion" sounds like a market-wide phenomenon. Unpacked, it is largely the financial behavior of a handful of cash-rich companies — a distinction that shapes everything that follows.

Tencent Is Deliberately Slowing Its Buybacks to Fund AI

Tencent's own pullback is central to why this year's total trails last year's. According to a Sept. 2 report compiled by Cailian Press, Tencent repurchased HK$112 billion in 2024 — the largest in the Hong Kong market — before that figure tumbled to HK$80 billion in 2025, a drop of about 29%. In the first eight months of 2026, Tencent has bought back about HK$29.1 billion. Daily buying intensity has cratered from more than 4 million shares at points during the 2024 market slump to 226,000 shares, worth about HK$100 million, on Sept. 1; Cailian Press's day-by-day tally of HKEX filings showed daily buybacks running near HK$300 million in mid-to-late August before tumbling to about HK$100 million from September.

Tencent's management has said, as reported by Cailian Press in March 2026, that it would sharply cut share repurchases to redirect funds toward AI, adding that 2025 capital expenditure of 79.2 billion yuan (about US$11 billion) — up 3% year over year — was already insufficient against rising computing costs. All figures above are media tallies and paraphrased company statements; specific amounts should be verified against transaction-by-transaction filings on the HKEX's HKEXnews disclosure platform.

That is what makes the "HK$100 billion" figure counterintuitive: the single biggest buyer is deliberately decelerating, shifting cash from shareholder returns into computing capacity. Everyone else's stake increases and buybacks are mostly in the hundreds of millions of Hong Kong dollars — nowhere near enough to close the gap Tencent's slowdown created.

Alibaba's Placement Shows Two Different Kinds of Spending

Alibaba supplied the most dramatic example of a related but distinct trade-off. On Aug. 23, the company announced a placing of 710 million new shares at HK$112.70 apiece, raising about HK$80 billion that it said would go toward AI infrastructure; it confirmed completion on Aug. 26. Alibaba's Hong Kong-listed shares fell sharply, dropping more than 8% intraday on Aug. 24, while its US-listed shares dipped about 4% in premarket trading.

Management responded by buying stock personally. According to the Shanghai Securities News, founder Jack Ma had accumulated more than HK$600 million in purchases by Aug. 25, while Chairman Joe Tsai and Chief Executive Officer Eddie Wu bought roughly HK$200 million of shares between them on Aug. 24–25. At Kingsoft Corp., Chairman Lei Jun made repeated purchases from Aug. 24 to 27, lifting his stake to 27.41%. Wen Jie, a director of the Hong Kong Society of Financial Analysts, told reporters that a placing paired with executive buying signals aligned interests, and that management adding to positions voluntarily suggests their view of the company's value doesn't hinge on short-term price swings.

The two figures should not be read as one story: roughly HK$80 billion is being raised from the market for AI capital spending, while about HK$800 million is being spent by individuals to counter dilution concerns. The former is capital expenditure; the latter is a signal. Treating Alibaba's stake increases alone as the headline would misread where the larger sum of money is actually going.

Elsewhere, the buying is smaller and more scattered. So far this year, executives or major shareholders at Sino Biopharmaceutical, Alisyn Biomedical-B, CStone Pharmaceuticals-B, Antengene-B and Kintor Pharmaceutical-B have all increased their holdings, though none of the amounts were disclosed. The Hang Seng Healthcare Index closed at 3,831.96 on Sept. 3, still down more than 50% from its 2021 peak. Founder Securities argued in a research note that Chinese innovative-drug makers have entered an earnings cycle built on overseas licensing revenue, with National Medical Products Administration data showing licensing deals worth more than US$60 billion in the first three months of 2026 alone — nearly half of the full-year 2025 total.

In the property-supply chain, Zuo Manlun, administrative president of China Lesso, bought 43.9091 million shares for about HK$166 million on July 8; Cen Zhiyong, an analyst at Wutong Research Institute, said the stock has fallen into a historic low range while its overseas business is expanding faster, prompting management to signal confidence through buying. Carmakers have moved too: Li Auto announced a US$1 billion buyback program in March valid through March 2027, Geely Automobile has executed more than HK$1.88 billion of a HK$2.3 billion program unveiled last October, and both MINIEYE and Great Wall Motor have each repurchased more than HK$100 million. Zhang Xiang, a researcher at the Automotive Industry Innovation Research Center of North China University of Technology, told reporters that carmakers' competitive focus is shifting from capacity expansion and price wars toward shareholder returns and market-cap management.

Two figures worth separating: "up to HKX"isaprogramceiling,while"HKX" is a program ceiling, while "HK X"isaprogramceiling,while"HKX already repurchased" is money actually spent. China Resources Beverage's HK$530 million buyback plan and Weilong Delicious's HK$200 million allocation are both ceilings; Mengniu Dairy's HK$143 million, covering 8.61 million shares through Sept. 2, is money already spent. Conflating the two makes a company's real buying look larger than it is.

What to Watch Next

Four things will show whether this shift is temporary or structural. First, whether HKEXnews filings start specifying cancellation as the intended use of repurchased shares, rather than allocation to employee share schemes. Second, whether Tencent's daily buyback value climbs back above HK$300 million or continues trending toward HK$100 million. Third, how much of Alibaba's HK$80 billion placing proceeds actually convert into disclosed AI capital spending in coming quarters. And fourth, whether the Hang Seng Healthcare Index can narrow its 50%-plus drawdown from 2021, and whether biotech companies begin disclosing the size of executive stake increases rather than leaving them unquantified.

What makes the HK$100 billion figure worth remembering isn't that it crossed a threshold — it's what sits underneath: companies are willing to buy their own shares at lower prices, but not willing to spend any more.

Risk disclosure: Data in this article are drawn from reports by the Shanghai Securities News and Cailian Press; the original tallies do not specify the underlying database or measurement basis. For details of individual buybacks and stake increases, refer to announcements on the HKEX's HKEXnews disclosure platform. This article compiles public information and